Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works

Human Lymphoid and Myeloid Cell Development in NOD/LtSz- scid IL2R γ null Mice Engrafted with Mobilized Human Hemopoietic Stem Cells,

Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,736 · see citing works

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · see citing works

Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses

Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479 · see citing works

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Depil, S., Duchateau, P. N., Grupp, S. A., Mufti, G. J., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,238 · see citing works

Multiple myeloma

Kumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,235 · see citing works

Diagnosis and Management of Multiple Myeloma

Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,054 · see citing works

Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding

Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,040 · see citing works

Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition

Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942 · see citing works

Phagocytosis checkpoints as new targets for cancer immunotherapy

Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y., & Weissman, I. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0183-z · Cited by 914 · see citing works

Multiple myeloma

Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 857 · see citing works

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

Liu, X., Pu, Y., Cron, K. R., Deng, L., Kline, J. P., Frazier, W. A., Xu, H., Peng, H., Fu, Y., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 770 · see citing works

The CD47-SIRPα Immune Checkpoint

Logtenberg, M. E. W., Scheeren, F. A., & Schumacher, T. N. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.011 · Cited by 750 · see citing works

General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold

Vincke, C., Loris, R., Saerens, D., Martínez‐Rodríguez, S., Muyldermans, S., & Conrath, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806889200 · Cited by 577 · see citing works

The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer

Matlung, H. L., Szilagyi, K., Barclay, N., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 563 · see citing works

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490 · see citing works

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 441 · see citing works

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2016) · Cell Research · doi:10.1038/cr.2016.142 · Cited by 396 · see citing works

A versatile system for rapid multiplex genome-edited CAR T cell generation

Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 395 · see citing works

Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex

King, M. A., Covassin, L., Brehm, M. A., Racki, W. J., Pearson, T., Leif, J., Laning, J. C., Fodor, W. L., Foreman, O., Burzenski, L. M., et al. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03933.x · Cited by 389 · see citing works

Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγ null humanized mice

Shultz, L. D., Saito, Y., Najima, Y., Tanaka, S., Ochi, T., Tomizawa, M., Doi, T., Sone, A., Suzuki, N., Fujiwara, H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000475107 · Cited by 366 · see citing works

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

Tai, Y., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 352 · see citing works

Targeting CD47 for cancer immunotherapy

Jiang, Z., Sun, H., Yu, J., Tian, W., & Song, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01197-w · Cited by 349 · see citing works

The proteasome and proteasome inhibitors in multiple myeloma

Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9707-8 · Cited by 342 · see citing works

Universal CARs, universal T cells, and universal CAR T cells

Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0677-2 · Cited by 315 · see citing works

Proteasome Inhibitor Drugs

Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309 · see citing works

Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond

Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305 · see citing works

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Hu, Y., Zhou, Y., Zhang, M., Ge, W., Li, Y., Yang, L., Wei, G., Han, L., Wang, H., Yu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3863 · Cited by 287 · see citing works

Affinity of human IgG subclasses to mouse Fc gamma receptors

Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg‐Thunnissen, S. N., Zimring, J. C., Rispens, T., & Vidarsson, G. (2017) · mAbs · doi:10.1080/19420862.2017.1323159 · Cited by 281 · see citing works

Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience

Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 258 · see citing works

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02182-7 · Cited by 257 · see citing works

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

Kim, D., Wang, J., Willingham, S. B., Martin, R. K., Wernig, G., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.141 · Cited by 249 · see citing works

Crosstalk between Human IgG Isotypes and Murine Effector Cells

Overdijk, M. B., Verploegen, S. A. B. W., Buijsse, A. O., Vink, T., Leusen, J. H. W., Bleeker, W. K., & Parren, P. W. H. I. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200356 · Cited by 224 · see citing works

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy

Jia, X., Yan, B., Tian, X., Liu, Q., Jin, J., Shi, J., & Hou, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60782 · Cited by 205 · see citing works

Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.

Steplewski, Z., Sun, L. K., Shearman, C. W., Ghrayeb, J., Daddona, P. E., & Koprowski, H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4852 · Cited by 204 · see citing works

Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy

Kagoya, Y., Guo, T., Yeung, B., Saso, K., Anczurowski, M., Wang, C.-H., Murata, K., Sugata, K., Saijo, H., Matsunaga, Y., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0508 · Cited by 179 · see citing works

Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia

Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3010 · Cited by 175 · see citing works

Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell–NK cell axis in murine hepatocellular carcinoma model

Wang, S., Wu, Q., Chen, T., Su, R., Pan, C., Qian, J., Huang, H., Yin, S., Xie, H., Zhou, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.011 · Cited by 167 · see citing works

Daratumumab in multiple myeloma

Nooka, A. K., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Heffner, T. L., Gupta, V. A., Sullivan, H. C., Neish, A. S., Dhodapkar, M. V., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32065 · Cited by 166 · see citing works

Emerging immunotherapies in multiple myeloma

Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 157 · see citing works

Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis

Hu, T., Liu, H., Liang, Z., Wang, F., Zhou, C., Zheng, X., Zhang, Y., Song, Y., Hu, J., He, X., et al. (2020) · Theranostics · doi:10.7150/thno.40860 · Cited by 156 · see citing works

Belantamab Mafodotin: First Approval

Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01404-x · Cited by 145 · see citing works

Allogeneic CAR Cell Therapy—More Than a Pipe Dream

Caldwell, K. J., Gottschalk, S. M., & Talleur, A. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618427 · Cited by 133 · see citing works

An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma

Xu, B., Tian, L., Chen, J., Wang, J., Ma, R., Dong, W., Li, A., Zhang, J., Chiocca, E. A., Kaur, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26003-6 · Cited by 110 · see citing works

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

Du, K., Li, Y., Liu, J., Chen, W., Wei, Z., Luo, Y., Liu, H., Qi, Y., Wang, F., & Sui, J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.006 · Cited by 107 · see citing works

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

Xie, Y. J., Dougan, M. L., Ingram, J. R., Pishesha, N., Fang, T., Momin, N., & Ploegh, H. L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0734 · Cited by 99 · see citing works

Signal‐regulatory protein α from the NOD mouse binds human CD 47 with an exceptionally high affinity – implications for engraftment of human cells

Kwong, L. S., Brown, M. H., Barclay, A. N., & Hatherley, D. (2014) · Immunology · doi:10.1111/imm.12290 · Cited by 96 · see citing works

Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer

Yu, L., Ding, Y., Wan, T., Deng, T., Huang, H., & Liu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.768115 · Cited by 95 · see citing works

Teclistamab: First Approval

Kang, C. (2022) · Drugs · doi:10.1007/s40265-022-01793-1 · Cited by 92 · see citing works

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

Lu, Q., Zhang, Z., Li, H., Zhong, K., Zhao, Q., Wang, Z., Wu, Z., Yang, D., Sun, S., Yang, N., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00768-w · Cited by 89 · see citing works

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma

Sun, J., Muz, B., Alhallak, K., Markovic, M., Gurley, S., Wang, Z., Guenthner, N., Wasden, K., Fiala, M. A., King, J. A., et al. (2020) · Cancers · doi:10.3390/cancers12020305 · Cited by 86 · see citing works

Nanobody-horseradish peroxidase fusion protein as an ultrasensitive probe to detect antibodies against Newcastle disease virus in the immunoassay

Sheng, Y., Wang, K., Lu, Q., Ji, P., Liu, B., Zhu, J., Liu, Q., Sun, Y., Zhang, J., Zhou, E., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0468-0 · Cited by 81 · see citing works

FDA approves first BCMA-targeted CAR-T cell therapy

Mullard, A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00063-1 · Cited by 81 · see citing works

Isatuximab: First Approval

Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01311-1 · Cited by 79 · see citing works

Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy

Tipanee, J., Samara-Kuko, E., Gevaert, T., Chuah, M. K., & VandenDriessche, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.006 · Cited by 76 · see citing works

FDA approves second BCMA-targeted CAR-T cell therapy

Mullard, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00048-8 · Cited by 68 · see citing works

Targeting Fc Receptor-Mediated Effects and the “Don't Eat Me” Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer

Tian, L., Xu, B., Teng, K.-Y., Song, M., Zhu, Z., Chen, Y., Wang, J., Zhang, J., Feng, M., Kaur, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1248 · Cited by 66 · see citing works

Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma

Rastgoo, N., Wu, J., Liu, M., Pourabdollah, M., Atenafu, E. G., Reece, D. E., Chen, W., & Chang, H. (2019) · Haematologica · doi:10.3324/haematol.2019.227579 · Cited by 62 · see citing works

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy

Chen, H., Yang, Y., Deng, Y., Wei, F., Zhao, Q., Liu, Y., Liu, Z., Yu, B., & Huang, Z. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003737 · Cited by 61 · see citing works

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Cao, X., Wang, Y., Zhang, W., Zhong, X., Gunes, E. G., Dang, J., Wang, J., Epstein, A. L., Querfeld, C., Sun, Z., et al. (2022) · Blood · doi:10.1182/blood.2021013901 · Cited by 59 · see citing works

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal

Yu, J., Li, S., Chen, D., Liu, D., Guo, H., Yang, C., Zhang, W., Zhang, L., Zhao, G., Tu, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01385-2 · Cited by 55 · see citing works

A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of rapamycin activation

Gupta, M., Dillon, S. R., Ziesmer, S. C., Feldman, A. L., Witzig, T. E., Ansell, S. M., Cerhan, J. R., & Novak, A. J. (2009) · Blood · doi:10.1182/blood-2008-09-179762 · Cited by 52 · see citing works

Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment

Wang, R., Zhang, C., Cao, Y., Wang, J., Jiao, S., Zhang, J., Wang, M., Tang, P., Ouyang, Z., Liang, W., et al. (2022) · Theranostics · doi:10.7150/thno.79367 · Cited by 49 · see citing works

Talquetamab: First Approval

Keam, S. J. (2023) · Drugs · doi:10.1007/s40265-023-01945-x · Cited by 48 · see citing works

Nanobody‑horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays

Lu, Q., Li, X., Zhao, J., Zhu, J.-H., Luo, Y., Duan, H. Q., Ji, P., Wang, K., Liu, B., Wang, X., et al. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0568-x · Cited by 47 · see citing works

Elranatamab: First Approval

Dhillon, S. (2023) · Drugs · doi:10.1007/s40265-023-01954-w · Cited by 47 · see citing works

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

Dacek, M. M., Kurtz, K. G., Wallisch, P., Pierre, S. A., Khayat, S., Bourne, C. M., Gardner, T. J., Vogt, K. C., Aquino, N., Younes, A., et al. (2023) · Blood · doi:10.1182/blood.2022016101 · Cited by 45 · see citing works

The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma

Sanchez, E., Smith, E. J., Yashar, M. A., Patil, S., Li, M., Porter, A. L., Tanenbaum, E. J., Schlossberg, R. E., Soof, C. M., Hekmati, T., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0538-x · Cited by 43 · see citing works

Elotuzumab: First Global Approval

Markham, A. (2016) · Drugs · doi:10.1007/s40265-016-0540-0 · Cited by 34 · see citing works

Human T cells depend on functional calcineurin, tumour necrosis factor-α and CD80/CD86 for expansion and activation in mice

Søndergaard, H., Kvist, P. H., & Haase, C. (2012) · Clinical & Experimental Immunology · doi:10.1111/cei.12051 · Cited by 33 · see citing works

Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands

Chang, Z., Hou, A. J., & Chen, Y. Y. (2020) · Nature Protocols · doi:10.1038/s41596-020-0294-8 · Cited by 25 · see citing works

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Paul, B. A., Liedtke, M., Khouri, J., Rifkin, R. M., Gandhi, M. D., Kin, A. D., Levy, M. Y., Silbermann, R. W., Cottini, F., Sborov, D. W., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-0975 · Cited by 20 · see citing works

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

Wilson, W. C., Richards, J. O., Puro, R. J., Andrejeva, G., Capoccia, B. J., Donio, M. J., Hiebsch, R. R., Chakraborty, P., Sung, V., & Pereira, D. S. (2020) · Blood · doi:10.1182/blood-2020-139655 · Cited by 20 · see citing works

TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.

Patel, K., Orlowski, R. Z., Doucette, K., Maris, M. B., Pianko, M. J., Ramchandren, R., Stevens, D. A., Vesole, D. H., Uger, R. A., Scheuber, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps8071 · Cited by 9 · see citing works

Multiple myeloma: signaling pathways and targeted therapy

Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

Martins, T. A., Kaymak, D., Tatari, N., Gerster, F., Hogan, S., Ritz, M.-F., Sabatino, V., Wieboldt, R., Bartoszek, E. M., McDaid, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54129-w · Cited by 54 · see citing works

Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S., & Yu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1378647 · Cited by 47 · see citing works

Recent advances in universal chimeric antigen receptor T cell therapy

Jiang, N., Yang, Z., Miao, H., Xing, S., Wang, S., & Li, N. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01737-8 · Cited by 39 · see citing works

The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050

Dou, X., Duan, G., Zhong, Y., Liu, Y., Peng, N., Lei, W., Qi, J., Zhou, M., Zhang, X., & Lu, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217440 · Cited by 34 · see citing works

The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency

Bao, Y.-T., Lv, M., Huang, X., & Zhao, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217771 · Cited by 11 · see citing works

CAR-T Therapy in Multiple Myeloma: Looking Beyond

Maiorana, G., Antolino, G., Verde, G. L., & Tafuri, A. (2024) · Hemato · doi:10.3390/hemato5020015 · Cited by 4 · see citing works

Blood cancer therapy with synthetic receptors and CRISPR technology

Zhang, H., Zhong, M., Zhang, J., & Chen, C. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107646 · Cited by 4 · see citing works

Antibody screening for tumor and immune hotspot targets: The frontier of new methods and technologies

Zhou, Y., Zou, Y., Lv, S., Tan, D., Li, G., Fu, W., Lei, C., Lu, M., & Hu, S. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101417 · Cited by 3 · see citing works

CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia

Li, H., Lu, Q., Yu, Z., Wu, Z., Zhu, Z., Li, J., Zhang, Z., Wang, Z., Yang, N., Chen, Y., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003588 · Cited by 3 · see citing works

Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions

Han, S. Z., Yue, J., Zheng, H., Huang, Y., Kong, D., Wei, G., Hu, Y., & Huang, H. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3061-8 · Cited by 2 · see citing works

Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease

Osborne, M., & Maher, J. F. (2025) · Biology · doi:10.3390/biology14121790 · Cited by 1 · see citing works

The immune‐metabolism interactome in efferocytosis: a new paradigm for the central nervous system diseases revealed by single‐cell sequencing analysis

Zhang, H., Li, W., Xiao, P., Lu, Z., Tian, Y., & Xu, Y. (2026) · The Journal of Pathology · doi:10.1002/path.70031 · Cited by 1 · see citing works

CAR-T and nanotechnology: A comparative Perspective on autoimmune disease and cancer

Pavithra, A. J., & Ragavendran, C. (2025) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2025.03.002 · Cited by 1 · see citing works

Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions

Wang, G., Gao, H., Xie, T., & Zi, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116996

BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma

Lu, Q., Li, H., Wu, Z., Zhu, Z., Zhang, Z., Yang, D., & Tong, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02512-6 · Cited by 19 · see citing works

Additional file 1 of BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma

Lu, Q., Li, H., Wu, Z., Zhu, Z., Zhang, Z., Yang, D., & Tong, A. (2024) · Figshare · doi:10.6084/m9.figshare.25893743

Targeting the CD47-SIRPalpha checkpoint in multiple myeloma

Sim, T. M., Chng, W. J., Liu, H., & Mel, S. D. (2025) · Discover Oncology · doi:10.1007/s12672-025-03312-6 · Cited by 2 · see citing works

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth

Sun, F., Cheng, Y., Wanchai, V., Guo, W., Mery, D. E., Xu, H., Gai, D., Siegel, E. R., Bailey, C., Ashby, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44873-4 · Cited by 54 · see citing works

CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth

Berahovich, R., Zhou, H., Xu, S., Wei, Y., Guan, J., Guan, J., Harto, H., Fu, S., Yang, K., Zhu, S., et al. (2018) · Cancers · doi:10.3390/cancers10090323 · Cited by 24 · see citing works